Technology, Healthcare Jul 25, 2021 04:25 PM (GMT+8)
Xiangxue pharmaceutical announced that in view of the changes in the current market environment and the impact of the epidemic situation, the controlling shareholder Kunlun investment and Hengshu No. 1 terminated the agreement to transfer the company's shares. Kunlun investment originally planned to transfer 9.98% of the company's shares to Hengshu No. 1.
This text is a result of machine translation.